Deep Tech Startups
5,913 companies tagged Deep Tech, with their investors and founders.
RAAAM Technologies develops GCRAM, an on-chip memory technology positioned as a drop-in replacement for SRAM that offers up to 50% area reduction and up to 10X lower power consumption while remaining compatible with standard CMOS fabrication. It targets semiconductor companies building chips for AI/ML, AR/VR, automotive, 5G, and data center high-performance compute applications.
2 investors
Radialis develops the Radialis PET Imager, an organ-targeted positron emission tomography system for high-resolution medical imaging of specific tissues and organs. The system is designed for use by healthcare providers in clinical settings to support cancer detection, treatment planning, and precision medicine applications.
2 investors
Radical Numerics develops AI models and architectures built for biology, including multimodal generative models trained on biological data to support genomic discovery and gene-editing. The company is behind the Evo and Evo 2 generative genomics models and aims to apply AI to biological research and biosecurity, including detection and response to biological threats.
2 investors
Rarity Bioscience develops ultra-sensitive mutation detection assays based on its patented superRCA dual-RCA technology, which amplifies single mutated DNA molecules into fluorescent particles for detection on standard flow cytometers. The research-use-only platform targets researchers working on measurable residual disease assessment, relapse and resistance detection, therapy response research, and drug development.
2 investors
Raven builds Prism, an ambient computer in the form of glasses that runs Linux with a color display and a 64-bit ARM processor, capable of running apps, streaming video, and on-device language models. The device offers an open ecosystem with Bluetooth, Wi-Fi, and support for third-party input and accessories for developers and makers.
2 investors
Rayni builds an AI assistant for scientific instruments that gives citation-backed, step-by-step troubleshooting and servicing guidance drawn from official manuals and a team's internal knowledge. It serves labs and field service teams supporting complex instruments, centralizing knowledge for faster issue resolution, training, and onboarding.
2 investors
Reaction Dynamics develops the Aurora rocket using a patented hybrid rocket engine to provide dedicated, cost-effective launches for small-satellite operators into Low Earth Orbit. Based in Canada, it aims to establish sovereign Canadian launch capability, with suborbital and orbital launches planned for 2026 and 2028.
2 investors
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform. It serves researchers analyzing gene expression at subcellular resolution, including in FFPE and degraded samples.
2 investors
Reasoner analyzes thousands of human behavioral and psychological signals β including what people say, choose, value, and avoid β to identify patterns unique to each individual. The product appears to focus on modeling emotional, cognitive, and social traits.
2 investors
ReAx is a chemoproteomics drug discovery company using its discovery platform to develop first-in-class and best-in-class therapies for challenging protein targets. The company brings together expertise in biology, chemistry, and computation.
2 investors
ReconLabs is a South Korean technology company focused on developing new technologies and products, with a team weighted toward R&D and graduate-level talent. The team page emphasizes its engineering and product-building focus but does not specify the product on this page.
2 investors
Software platform to improve drug discovery
2 investors
Regor is a drug discovery company that uses a computational platform (rCARD) to identify and optimize preclinical small-molecule candidates in metabolism, oncology, and immunology, which it licenses to pharmaceutical companies for clinical development. Its pipeline includes RGT-075, an oral GLP-1R agonist for obesity and type 2 diabetes, and next-generation CDK inhibitors for breast cancer.
2 investors
Relativity Networks develops Hollow Core Fiber (HCF) optics that replace glass with air to move data nearly 50% faster, reducing latency over distance. The technology targets hyperscalers and data center operators, allowing them to build facilities in power-rich or renewable-energy locations away from constrained urban grids.
2 investors
Rendezvous Robotics develops self-assembling spacecraft made of modular tiles that autonomously assemble in orbit using electromagnetic control, enabling large-scale structures that cannot fold into a rocket fairing. It targets defense (ISR, protected communications, missile tracking), direct-to-device communications, and orbital compute applications.
2 investors
Repertoire's Decode platform focuses on mapping the immune synapse β the interactions between T cell receptors, epitopes, and HLA molecules β to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.
2 investors
Resonant Link Inc. developed wireless power technology and is no longer operating as an active business, now managing and licensing its patent portfolio for non-medical wireless power. Its medical device wireless power work continues through a related entity, Resonant Link Medical.
2 investors
Retym develops DSP (digital signal processing) and ADC/DAC technologies for AI infrastructure and cloud connectivity, with expertise in analog design, error correction, and optical communications.
2 investors
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease. It operates in the RNA-targeted drug development space.
2 investors
Rhea Space Activity (RSA) is an astrophysics technology developer building systems for national security, including infrared satellites, directed energy, artificial intelligence, small satellites, and autonomous underwater vehicles. It serves governments and defense forces, with a focus on lunar and deep space applications for the U.S. and allied nations.
2 investors
Ribbon produces cell-free synthetic DNA made without bacteria, avoiding the contamination, delays, and design limits of cloning-based workflows. Its products, including a kit-based on-site synthesis system, target mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing applications.
2 investors
Ribo Life Science (Ribocure/ηεηη©, HKEX: 06938.HK) develops RNA interference (RNAi) technology and industrializes small nucleic acid (siRNA) drugs, with an integrated research platform covering delivery and chemical modification technologies. Its pipeline targets cardiovascular, metabolic, renal, and liver diseases, with a focus on chronic disease treatment.
2 investors
CM Venture is a venture capital firm that invests in science-backed, early-stage technologies across digital transformation, advanced materials, energy systems, and applied AI. It partners with corporate venture arms, universities, endowments, and impact and financial investors to scale industrial innovations.
2 investors
RISC Zero builds verifiable computation technology using zero-knowledge proofs, allowing anyone to cryptographically confirm that a computation's output is correct regardless of who ran it. It targets use cases such as proving financial transactions are performed correctly and compliantly while preserving privacy, and addressing trust gaps in software supply chains.
2 investors